WIXOM, Mich., Jan. 31, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products focused on the end-stage-renal-disease (ESRD) market, announced today that the National Institutes of Health (NIH) sponsored clinical study for Soluble Ferric Pyrophosphate (SFP), Rockwell’s physiological iron-maintenance-therapy drug, has entered active treatment phase with the initiation of dosing.
